Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
about
The epigenetic landscape of acute myeloid leukemiaJAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative NeoplasmsMpl traffics to the cell surface through conventional and unconventional routesPersonalized management of essential thrombocythemia-application of recent evidence to clinical practiceRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedGenomic diversity in myeloproliferative neoplasms: focus on myelofibrosisRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsGenomic profiling of B-progenitor acute lymphoblastic leukemiaPolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementAdvances in the management of myelofibrosisJanus kinase inhibitors: jackpot or potluck?Next generation sequencing of acute myeloid leukemia: influencing prognosis.Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaClinical Correlates of Autosomal Chromosomal Abnormalities in an Electronic Medical Record-Linked Genome-Wide Association Study: A Case Series.Clinical Correlates of Autosomal Chromosomal Abnormalities in an Electronic Medical Record-Linked Genome-Wide Association Study: A Case SeriesTet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformationTen-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in miceMouse models of myeloproliferative neoplasms: JAK of all gradesIntegrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Immunomodulatory agents in myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibEmerging drugs for myelofibrosis.Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.Ruxolitinib for myelofibrosis--an update of its clinical effects.Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasmsComparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisMutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.Research and progress on ClC‑2 (Review).Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay.SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm
P2860
Q21284742-BAEBA66F-7B93-4B0A-B0AC-5A52253D16AFQ21285040-B8FDCCE1-1222-4FCC-BCCE-7DB6C09999F0Q24299221-D9E5AE93-3A7C-4952-B923-124A10F0421BQ24632447-487E63FB-CF50-4264-888C-4F10A7A00C75Q26738514-6F010AFB-11EA-49C6-8E98-769FD3F9BB5EQ26770330-4069B68E-6D6A-418B-A32D-1F401E1E7D39Q26772881-17EE604D-A1BF-4A53-87BA-53A854CC6952Q26779929-BF707B96-64F8-4061-A99A-E5F0837DCCD5Q26829976-BBC2A627-57DC-4A12-894F-B070C3710673Q26851894-DCA8EC9D-F954-4C53-8BD1-DCE95A410BFAQ27008072-9CF9F0A8-3F84-4328-885F-EC2C99B85314Q27027230-D6E884C8-829A-495A-B86F-9B39351D9239Q27690776-D260A873-DBEE-40EB-B2DD-AC10683DE2E5Q28084727-365F5655-F8AE-4DE1-BA90-0F84506DC2B6Q28307278-6C57AA42-AC4F-4EF9-AD9B-C5FB204F6997Q28385298-7F220035-5E39-44F7-B965-6C332B582D4DQ28392193-AE7B89EC-22E8-45BA-B140-64D71662D7EAQ28508217-2CD61529-E59C-40B3-AF42-08250F35CCF4Q28511594-550238A0-35CC-4F75-8F86-69BD31A45765Q28744478-8BC7C3DF-B7D5-430D-91EF-0F816B2AD7A0Q31019526-EB2DAA37-8AA6-4670-8AA2-554B67102FADQ31110460-8575245C-BC20-4802-93CB-A77C896702C2Q33397674-12D8F5E9-C60F-4308-96F5-302CBEA5A050Q33397838-8C63F24C-BD21-4068-916E-F4796E69D85BQ33398180-704BD833-2C77-41B3-931C-B3D710A75C6CQ33401615-72DE5322-9C8D-49D9-B4D2-676AE103A6FBQ33402522-03FF8135-AE54-473A-805C-8076E7256965Q33404574-A10AA162-85BF-4A13-911C-A1AB643362B8Q33405985-9D0C377E-5AE2-40F9-84C3-A44513FD61C9Q33406238-78B46BC4-3BB1-4453-9826-2E8C3593E035Q33406648-CED2953C-B8FB-47C2-9E7A-37117B76D675Q33411502-4B7709D8-930B-4AE0-92D1-D11AC8536D2AQ33573793-712EDD86-B689-431F-BA39-4F7DC5C734A7Q33595912-00BD921E-1EE2-422E-8230-757393171233Q33667448-39E2B245-7633-4A20-BC14-168C55EB4C03Q33828111-BCCA0458-02BB-4AAD-B96A-CEDFEA400F96Q34075358-7C8BBEE6-D88E-4FFF-97BD-454C9BB8B3AEQ34081581-BC11C9A0-8F64-4228-B277-B5F6AFFECF7AQ34150008-6A95CC33-4E67-4B0C-AE1C-148661D5EB00Q34154772-F2FB54D8-E51F-4E73-9A52-99AAFC173DF2
P2860
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@ast
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@en
Novel mutations and their func ...... T2, ASXL1, CBL, IDH and IKZF1.
@nl
type
label
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@ast
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@en
Novel mutations and their func ...... T2, ASXL1, CBL, IDH and IKZF1.
@nl
prefLabel
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@ast
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@en
Novel mutations and their func ...... T2, ASXL1, CBL, IDH and IKZF1.
@nl
P2860
P921
P3181
P356
P1433
P1476
Novel mutations and their func ...... ET2, ASXL1, CBL, IDH and IKZF1
@en
P2860
P2888
P304
P3181
P356
10.1038/LEU.2010.69
P5008
P577
2010-06-01T00:00:00Z
P5875
P6179
1012024457